Eli Lilly and Company
Explore Eli Lilly and Company
Core profile pages, annual revenue records, and related research hubs for this company.
CorpDigest
Eli Lilly and Company
Explore Eli Lilly and Company
Core profile pages, annual revenue records, and related research hubs for this company.
Annual Revenue
FY2023 Revenue
$34.1B
▲ 19.6% vs FY2022 ($28.5B)
Source: Annual report / company filing
Eli Lilly and Company reported $34.1B in revenue for fiscal year 2023. This represents a growth of 19.6% compared to the 2022 figure of $28.5B. In 2024, revenue increased to $45.0B.
Revenue accelerated 19.6 percent to $34.1 billion in 2023, powered by tirzepatide's expansion and Zepbound's November obesity approval.
| Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $65.2B | — | +44.8% |
| FY2024 | $45.0B | $10.6B | +31.9% |
| FY2023 | $34.1B | — | +19.6% |
| FY2022 | $28.5B | — | +0.8% |
| FY2021 | $28.3B | — | +15.5% |
| FY2020 | $24.5B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.